IMR Press / EJGO / Volume 41 / Issue 3 / DOI: 10.31083/j.ejgo.2020.03.5156
Open Access Original Research
Relationship between usefulness of irinotecan and pegylated liposomal doxorubicin therapy and the UGT1A1 genotype in patients with recurrent ovarian cancer (TGCU 104 study)
Show Less
1 Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka 020-8505, Japan
2 Department of Obstetrics and Gynecology, Hirosaki University School of Medicine, Hirosaki, Japan
3 Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan
4 Department of Obstetrics and Gynecology, Yamagata University Faculty of Medicine, Yamagata, Japan
5 Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, Fukushima, Japan
6 Department of Obstetrics and Gynecology, Takagi Hospital, Okawa, Japan
Eur. J. Gynaecol. Oncol. 2020 , 41(3), 380–385; https://doi.org/10.31083/j.ejgo.2020.03.5156
Submitted: 6 February 2019 | Accepted: 16 July 2019 | Published: 15 June 2020
Abstract

Objective: The authors investigated the relationship between the usefulness of CPT-11 + PLD combination therapy and the UGT1A1 genotype. Materials and Methods: Forty-one patients who provided informed consent were divided into the following two groups according to UGT1A1 genotypes: wild type and non-wild type. Adverse events, antitumor effect, and outcomes were compared between these two groups. Results: Twenty-three patients were wild type and 18 were non-wild type for UGT1A1. A total of 94 and 73 treatment cycles were prescribed to the wild-type and non-wild-type groups, respectively. No significant differences in the incidence of any grade 3 or higher adverse events were observed between the two groups. However, the next treatment cycle was postponed in 9.6% of the wildtype group and 12.3% of the non-wild-type group (p = 0.891). The antitumor effects as assessed by response rate were 26.1% in the wildtype group and 55.6% in the non-wild-type group (p = 0.054). The median observation period was 13 months. The median progression-free survival was three months in the wild-type group vs. five months in non-wild-type group (p = 0.913), while the median overall survival was 24 vs. 22 months (p = 0.535). Conclusions: This study did not demonstrate a statistically significant difference in the usefulness of CPT-11 + PLD combination therapy for recurrent ovarian cancer between the two groups of UGT1A1 genotypes. This study was considered to have significance as the first study conducted in Japan to prospectively evaluate the relationship between the usefulness of CPT-11-based chemotherapy and the UGT1A1 genotype for recurrent ovarian cancer.

Keywords
Recurrent ovarian cancer
Chemotherapy
CPT-11
PLD
UGT1A1
Figures
Figure 1.
Share
Back to top